After Amgen earlier this year suffered a third consecutive loss in its high-profile PCSK9 patent feud with Sanofi and Regeneron, the company faced two choices: …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
